Therefore the VEGFR2/VEGF signaling axis is an attractive therapeutic target in the treatment of conditions characterized by aberrant angiogenesis, such as cancer, and the common childhood tumor, infantile hemangioma. This evidence concerns the gene VEGFA and capillary hemangioma.